公开(公告)号：US20100280987A1

公开(公告)日：2010-11-04

申请号：US12761772

申请日：2010-04-16

申请人： Andrey Loboda ,  Michael Nebozhyn ,  Theresa Zhang ,  James W. Watters ,  Pearl S. Huang ,  Michael Chastain ,  Richard A. Klinghoffer

发明人： Andrey Loboda ,  Michael Nebozhyn ,  Theresa Zhang ,  James W. Watters ,  Pearl S. Huang ,  Michael Chastain ,  Richard A. Klinghoffer

IPC分类号： G06N5/02 ,  G06F19/00

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  G16B20/00 ,  G16B25/00

摘要： Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of RAS pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating RAS pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated RAS signaling pathway; determining whether an agent modulates the RAS signaling pathway in sample; predicting response of a subject to an agent that modulates the RAS signaling pathway; assigning treatment to a subject; and evaluating the pharmacodynamic effects of cancer therapies designed to regulate RAS pathway signaling.

摘要翻译： 公开了用于评估细胞样品或受试者中RAS途径信号传导的调节状态的方法，生物标志物和表达特征。 更具体地，本发明的几个方面提供了一组基因，其可以用作用于评估样品中RAS途径去调节状态的生物标志物和基因特征; 将细胞样品分类为具有去调节或调节的RAS信号传导途径; 确定试剂是否调制样品中的RAS信号通路; 预测受试者对调节RAS信号通路的药剂的反应; 为受试者分配治疗; 并评估旨在调节RAS途径信号传导的癌症疗法的药效学作用。